MULTICENTER, STUDY OF ARIMOCLOMOL IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是评估在80名ALS患者治疗12周后，三种剂量的阿利莫洛尔与安慰剂的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to assess the safety and tolerability of Arimoclomol at three dosages as compared with placebo over 12 weeks of treatment in 80 patients with ALS.